O'Brien James M, Abraham Edward
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Box C272, Denver, CO 80262, USA.
Clin Chest Med. 2003 Dec;24(4):521-48, v. doi: 10.1016/s0272-5231(03)00102-3.
The clinical spectrum of sepsis, severe sepsis, and septic shock is responsible for a growing number of deaths and excessive health care expenditures. Until recently, despite multiple clinical trials, no intervention provided a beneficial outcome in septic patients. Within the last 2 years, studies that involved drotrecogin alfa (activated), corticosteroid therapy, and early goal-directed therapy showed efficacy in those with severe sepsis and septic shock. These results have provided optimism for reducing sepsis-related mortality.
脓毒症、严重脓毒症和脓毒性休克的临床范围导致死亡人数不断增加，医疗保健支出过高。直到最近，尽管进行了多项临床试验，但没有一种干预措施能给脓毒症患者带来有益的结果。在过去两年中，涉及活化蛋白C、皮质类固醇治疗和早期目标导向治疗的研究表明，这些治疗方法对严重脓毒症和脓毒性休克患者有效。这些结果为降低脓毒症相关死亡率带来了希望。
